Drug intelligence / Profile preview

atezolizumab + bevacizumab + capecitabine

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of atezolizumab (a PD-L1 inhibitor), bevacizumab (a VEGF inhibitor), and capecitabine (a chemotherapy agent). This regimen combines immunotherapy, anti-angiogenesis therapy, and chemotherapy approaches for cancer treatment. It has been studied primarily for metastatic colorectal cancer, though clinical trials showed limited clinical benefit compared to capecitabine and bevacizumab alone.

Targets

VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)

Beyond the preview

Go deeper on atezolizumab + bevacizumab + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + bevacizumab + capecitabine.

Explore the full profile